Natixis Acquires Shares of 94,500 Inari Medical, Inc. (NASDAQ:NARI)

Natixis bought a new position in Inari Medical, Inc. (NASDAQ:NARI) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 94,500 shares of the company’s stock, valued at approximately $4,824,000. Natixis owned approximately 0.16% of Inari Medical as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of NARI. PNC Financial Services Group Inc. raised its holdings in Inari Medical by 5.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,550 shares of the company’s stock valued at $130,000 after acquiring an additional 128 shares during the period. Arizona State Retirement System grew its position in shares of Inari Medical by 0.9% in the fourth quarter. Arizona State Retirement System now owns 15,196 shares of the company’s stock valued at $776,000 after purchasing an additional 129 shares in the last quarter. Quadrant Capital Group LLC raised its stake in shares of Inari Medical by 12.3% during the 4th quarter. Quadrant Capital Group LLC now owns 1,301 shares of the company’s stock valued at $66,000 after purchasing an additional 143 shares during the period. Ieq Capital LLC lifted its holdings in Inari Medical by 0.3% during the 4th quarter. Ieq Capital LLC now owns 50,198 shares of the company’s stock worth $2,563,000 after purchasing an additional 145 shares in the last quarter. Finally, HighTower Advisors LLC boosted its stake in Inari Medical by 0.4% in the 4th quarter. HighTower Advisors LLC now owns 62,202 shares of the company’s stock worth $3,175,000 after purchasing an additional 234 shares during the period. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on NARI. Piper Sandler increased their price target on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a report on Tuesday, January 7th. BTIG Research reiterated a “neutral” rating on shares of Inari Medical in a research note on Wednesday, January 8th. William Blair reaffirmed a “market perform” rating on shares of Inari Medical in a report on Tuesday, January 7th. Canaccord Genuity Group reissued a “hold” rating and set a $80.00 price objective (up previously from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Finally, Wells Fargo & Company restated an “equal weight” rating and issued a $80.00 target price (up from $65.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Twelve research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Inari Medical currently has a consensus rating of “Hold” and a consensus target price of $68.00.

Inari Medical Price Performance

NASDAQ:NARI opened at $79.97 on Monday. The company has a market capitalization of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02. The business has a 50 day moving average of $79.97 and a 200 day moving average of $65.81. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $79.99.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.